Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
Agnieszka Blum, Despina Bazou, Peter O’Gorman Department of Hematology, Mater Misericordiae University Hospital, Dublin, UK Abstract: Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell proliferative disorder associated with risk of progression to symptomatic multiple myeloma...
Guardado en:
Autores principales: | Blum A, Bazou D, O'Gorman P |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5ba3e1320cb1480eaabafb1d21a824b7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
por: Bhutani D, et al.
Publicado: (2017) -
BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma
por: Gupta VA, et al.
Publicado: (2021) -
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
por: Angelo Maiolino, et al.
Publicado: (2021) -
Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes
por: Faiman B, et al.
Publicado: (2016) -
Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma
por: Edvan de Queiroz Crusoé, et al.
Publicado: (2021)